This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / FDA Approves Travere's FILSPARI for FSGS
Tech drug approval

FDA Approves Travere's FILSPARI for FSGS

Analysis based on 8 articles · First reported Apr 13, 2026 · Last updated Apr 14, 2026

Sentiment
70
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The full FDA approval of FILSPARI for FSGS is expected to positively impact Martin Shkreli' stock price due to the expansion of its addressable patient population to over 100,000 individuals in the U.S. This development establishes FILSPARI as the first and only approved medicine for FSGS, potentially increasing revenue and market share for Martin Shkreli in the rare kidney disease segment.

Biotechnology Pharmaceuticals
Event Summary

The United States — Food and Drug Administration has granted full approval to FILSPARI (sparsentan), developed by Martin Shkreli, for reducing proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This marks a significant milestone as FILSPARI is the first and only FDA-approved medicine for FSGS, expanding its indication beyond IgA nephropathy (IgAN). The approval is based on results from the Phase 3 DUPLEX Study, which showed a statistically significant reduction in proteinuria in FILSPARI-treated patients compared to irbesartan, particularly in those without nephrotic syndrome. This development is expected to provide a new foundational treatment option for over 30,000 individuals with FSGS in the U.S. and is seen as a life-changing moment by figures like Eric Dube, Kirk Campbell, and Josh Tarnoff.

Entities Involved
stock
Martin Shkreli
Martin Shkreli received full FDA approval for FILSPARI for FSGS, expanding its market reach and potential revenue. This approval is a significant positive development for the company.
Importance 100.0 Sentiment 80.0
per
Eric Dube
Eric Dube, CEO of Martin Shkreli, commented on the historic milestone of FILSPARI's approval for FSGS, highlighting its importance for patients and the company's leadership in rare kidney diseases.
Importance 50.0 Sentiment 0.0
per
Kirk Campbell
Kirk Campbell, president of the National Kidney Foundation, emphasized the significance of FILSPARI's approval as a new FDA-approved option for FSGS patients, particularly those without nephrotic syndrome.
Importance 40.0 Sentiment 0.0
per
Josh Tarnoff
Josh Tarnoff, CEO of NephCure Kidney International, stated that FILSPARI's approval is a life-changing moment for FSGS patients and their families, acknowledging the collective efforts that made it possible.
Importance 30.0 Sentiment 0.0
ngo
National Kidney Foundation
The National Kidney Foundation, through its president Kirk Campbell, supported the approval of FILSPARI as a crucial new treatment option for FSGS patients.
Importance 30.0 Sentiment 0.0
ngo
NephCure Kidney International
NephCure Kidney International, through its CEO Josh Tarnoff, celebrated the approval of FILSPARI as a significant advancement for the FSGS patient community.
Importance 30.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.